Lyotropic Therapeutics, Inc.
Patent Owner
Stats
- 25 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Feb 06, 2018 most recent publication
Details
- 25 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,099 Total Citation Count
- Jun 07, 1995 Earliest Filing
- 11 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9394339 Stabilized formulations of peptides and proteins protecting against non-enzymatic degradationSep 05, 14Jul 19, 16[A61K, C07K]
8858927 Method for protection of peptides or proteins against non-enzymatic deamidationDec 19, 08Oct 14, 14[A61K]
8449863 Stabilized uncoated particles of reversed liquid crystalline phase materialsMar 25, 10May 28, 13[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2014/0105,989 Treatment Methods with Low-Dose, Longer-Acting Formulations of Local Anesthetics and Other AgentsAbandonedDec 23, 13Apr 17, 14[A61K]
2011/0177,169 OPHTHALMIC FORMULATIONS OF REVERSED LIQUID CRYSTALLINE PHASE MATERIALS AND METHODS OF USINGAbandonedJul 09, 10Jul 21, 11[A61K, B82Y, A61P]
2005/0119,340 Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agentsAbandonedOct 08, 04Jun 02, 05[A61K]
2004/0156,816 Lipid-drug complexes in reversed liquid and liquid crystalline phasesAbandonedAug 06, 03Aug 12, 04[A61K]
2004/0022,820 Reversed liquid crystalline phases with non-paraffin hydrophobesAbandonedJun 13, 03Feb 05, 04[A61K]
2003/0232,340 Nanoporous particle with a retained targetAbandonedJun 13, 02Dec 18, 03[C12Q, C12M, G01N]
6121234 Use of essential oils to increase bioavailability of orally administered pharmaceutical compoundsExpiredFeb 06, 98Sep 19, 00[A61K]
5962522 Propyl gallate to increase bioavailability of orally administered pharmaceutical compoundsExpiredSep 05, 97Oct 05, 99[A61K]
5916566 Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compoundsExpiredFeb 11, 98Jun 29, 99[A61K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.